

This promotional symposium is organised and fully funded by Pierre Fabre Ltd and is intended for UK HCPs only.

[Click here](#) for prescribing information for Great Britain

[Click here](#) for prescribing information for Northern Ireland

Exploring long-term outcomes in patients with BRAF-mutant metastatic melanoma

BRAFTOVI in combination with MEKTOVI is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation^{1,2}

UK Oncology Forum

Friday 17 June 2022, 13:15–14:00

International Convention Centre Belfast

The chair of this session, **Prof Ruth Plummer**, Consultant Medical Oncologist at Newcastle Hospitals NHS Foundation Trust, will be joined by **Prof Mario Mandalà**, Associate Professor of Medical Oncology at the University of Perugia, Italy.

Together, the faculty will:

- **Review** the five-year data of commonly used targeted therapies for BRAF-mutant metastatic melanoma patients
- **Explore** how these data translate to clinical practice via real-world experience sharing
- **Discuss** their responses to questions from the audience

Agenda

Session	Speaker	Time
Welcome and introduction	Prof Ruth Plummer	3 mins
Five-year data of dabrafenib + trametinib for BRAF-mutant metastatic melanoma	Prof Ruth Plummer	7.5 mins
Five-year data of BRAFTOVI in combination with MEKTOVI for BRAF-mutant metastatic melanoma	Prof Mario Mandalà	7.5 mins
Presentation of case studies	Prof Ruth Plummer and Prof Mario Mandalà	15 mins
Panel discussion and Q&A	All	10 mins
Closing remarks	Prof Ruth Plummer	2 mins

We look forward to welcoming you in person to what promises to be an insightful and thought-provoking symposium.

1. Pierre Fabre Ltd. BRAFTOVI (encorafenib) Summary of Product Characteristics.
2. Pierre Fabre Ltd. MEKTOVI (binimetinib) Summary of Product Characteristics.

Pierre Fabre-marketed products will be discussed at this promotional symposium. Any discussion on Pierre Fabre products will be restricted to the terms of the product licence. Healthcare professionals are recommended to consult the summary of product characteristics at all times.

Adverse events should be reported. In the UK, reporting forms and information can be found at the Yellow Card Scheme Website: <https://yellowcard.mhra.gov.uk/> or search for MHRA Yellow Card in the Google Play or Apple App Store.

Adverse events should also be reported to Pierre Fabre Ltd: UK telephone 0800 0855 292, email uk_mi@pierre-fabre.com;